Adcendo Raises $75 Million in Series C Funding
Adcendo, a biotechnology company focusing on the development of Antibody-Drug Conjugates (ADCs) for cancer treatment, has successfully raised $75 million in a Series C funding round. The round was led by Jeito Capital, with participation from a diverse group of investors including BPI France, Dawn Biopharma, EIFO, Gilde Healthcare, HealthCap, KKR, Logos Capital, Novo Holdings, OrbiMed, Pontifax Venture Capital, RA Capital Management, Surveyor, TCGX, TPG, Venrock, Vida Ventures, and Ysios Capital.
Focus on ADC Pipeline Expansion
The newly acquired funds will primarily be used to expand Adcendo's clinical ADC pipeline. ADCs are targeted therapies that combine the specificity of antibodies with the cancer-killing ability of cytotoxic drugs. This approach allows for more precise targeting of cancer cells while minimizing damage to healthy cells. The company aims to leverage this funding to accelerate the development and potential commercialization of its ADC candidates.
Leadership and Vision
Michael Pehl, CEO of Adcendo, is at the helm of this ambitious project. Under his leadership, the company plans to advance its ADC programs into later-stage clinical trials. "This funding round allows us to push forward with our mission to develop targeted therapies that can make a significant difference in cancer treatment," Pehl stated.
Diverse Investor Backing
Jeito Capital spearheaded the investment, marking a significant vote of confidence in Adcendo's innovative approach to cancer therapy. The participation of a wide range of investors underscores the strong interest in ADC technology and its potential impact on the oncology field.
Strategic Use of Funds
The $75 million investment will be strategically deployed to enhance Adcendo's clinical capabilities and expand its research and development efforts. The company plans to focus on advancing its lead ADC candidates through critical clinical stages, aiming to bring effective cancer treatments to market more swiftly.
This substantial injection of capital is a testament to the promise of ADCs in revolutionizing cancer treatment and positions Adcendo to make significant strides in its clinical programs.